Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy
- PMID: 20136916
- DOI: 10.1111/j.1529-8019.2009.01281.x
Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy
Abstract
Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) index were measured at follow-up visits at 4 and 8 months. Nonparametric test of Mann-Whitney was used to detect the differences between patient groups. Fisher's exact test was performed to evaluate the different results depending on the therapeutic changes of BMI. There was a strong prevalence of overweight-obese individuals in the group with a mean BMI of 30.59 +/- 6.94. Waist circumference was also above normal in the majority of the patients. Obese patients had a PASI index higher than the average of the whole group (25.03 +/- 12.43), with grade III obese patients having an average PASI of 44 +/- 3.37. At the first and second follow-ups, patients who put on weight did not achieve PASI 50; patients who had a stable weight presented variable response to treatment, while patients who decreased their weight achieved PASI 90 or PASI 75 even when not responding at the first. Further studies are needed to understand if the poor response observed in heavier patients is due to biological drugs pharmacokinetics or because therapy should be BMI based rather than administered in fixed doses, posing then an ethical consideration.
Similar articles
-
The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.Expert Opin Biol Ther. 2014 Jun;14(6):749-56. doi: 10.1517/14712598.2014.900541. Epub 2014 Mar 24. Expert Opin Biol Ther. 2014. PMID: 24661040 Clinical Trial.
-
Initial experience with routine administration of etanercept in psoriasis.Br J Dermatol. 2006 Oct;155(4):808-14. doi: 10.1111/j.1365-2133.2006.07432.x. Br J Dermatol. 2006. PMID: 16965432
-
Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.Dermatology. 2008;217(4):365-73. doi: 10.1159/000156599. Epub 2008 Sep 23. Dermatology. 2008. PMID: 18810241
-
Obesity and psoriasis: body weight and body mass index influence the response to biological treatment.J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1007-11. doi: 10.1111/j.1468-3083.2011.04065.x. Epub 2011 Apr 15. J Eur Acad Dermatol Venereol. 2011. PMID: 21492252 Review.
-
[Psoriasis and obesity: a review and practical recommendations].Actas Dermosifiliogr. 2011 Sep;102(7):505-9. doi: 10.1016/j.ad.2011.03.010. Epub 2011 May 20. Actas Dermosifiliogr. 2011. PMID: 21601173 Review. Spanish.
Cited by
-
The influence of body weight of patients with chronic plaque psoriasis on biological treatment response.Postepy Dermatol Alergol. 2020 Apr;37(2):168-173. doi: 10.5114/ada.2020.94835. Epub 2020 May 5. Postepy Dermatol Alergol. 2020. PMID: 32489349 Free PMC article. Review.
-
Impact of Obesity on the IL-6 Immune Marker and Th17 Immune Cells in C57BL/6 Mice Models with Imiquimod-Induced Psoriasis.Int J Mol Sci. 2023 Mar 15;24(6):5592. doi: 10.3390/ijms24065592. Int J Mol Sci. 2023. PMID: 36982669 Free PMC article.
-
The Effect of a Ketogenic Diet versus Mediterranean Diet on Clinical and Biochemical Markers of Inflammation in Patients with Obesity and Psoriatic Arthritis: A Randomized Crossover Trial.Int J Mol Sci. 2024 Feb 20;25(5):2475. doi: 10.3390/ijms25052475. Int J Mol Sci. 2024. PMID: 38473723 Free PMC article. Clinical Trial.
-
Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist.Int J Environ Res Public Health. 2016 Jul 22;13(5):743. doi: 10.3390/ijerph13070743. Int J Environ Res Public Health. 2016. PMID: 27455297 Free PMC article. Review.
-
Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis.Pharmaceutics. 2021 Jul 11;13(7):1064. doi: 10.3390/pharmaceutics13071064. Pharmaceutics. 2021. PMID: 34371756 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical